| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Original Articles |
From the Departments of Surgical Oncology (HLvW, PAMH, JThMP), Nuclear Medicine/PET-center (PLJ), Gastroenterology (HMvD), and Office for Medical Technology Assessment (HG), Groningen University Hospital, The Netherlands.
Address correspondence and reprint requests to: John Th.M. Plukker, Department of Surgical Oncology, University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands; Fax: 31-50-361-48-73.
 |
Abstract |
|---|
Background: 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) is valuable in staging of esophageal cancer. However, FDG-PET may falsely upstage patients leading to incorrect exclusion from surgical treatment. This study was performed to determine the false-positive rate and possible causes.
Methods: The rate of false-positive lesions on FDG-PET was documented in 86 out of a group of 98 patients. Lesions were defined as false positive when pathological examination was negative or as absence of tumor activity within 6 months of follow-up. To evaluate the influence of a learning curve on the false-positive rate, the PET scans were revised recently.
Results: False-positive lesions were found in 13 patients (13 of 86; 15%). FDG-PET incorrectly revealed only locoregional node metastases in 5 patients in whom surgery with curative intent was performed. Ten lesions in the other 8 patients were classified as distant organ or as nonregional node metastases (M1a/1b). Finally, 5 patients upstaged to M1a/1b underwent a curative resection. The number of false-positive lesions decreased from 16 to 5 (6%) after revision.
Conclusions: Proper interpretation of FDG-PET in staging esophageal cancer is impeded by false-positive results. Even after completion of the learning curve, positive FDG-PET findings still have to be confirmed by additional investigations.
Key Words: Esophageal cancer, Positron emission tomography, 18-F-fluorodeoxyglucose, False-positive findings
This article has been cited by other articles:
 |
|
 |
|
  S. G. Little, T. W. Rice, B. Bybel, D. P. Mason, S. C. Murthy, G. W. Falk, L. A. Rybicki, and E. H. Blackstone Is FDG-PET indicated for superficial esophageal cancer? Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 791 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yuan, Y. Yu, K.S. C. Chao, Z. Fu, Y. Yin, T. Liu, S. Chen, X. Yang, G. Yang, H. Guo, et al. Additional Value of PET/CT over PET in Assessment of Locoregional Lymph Nodes in Thoracic Esophageal Squamous Cell Cancer J. Nucl. Med., August 1, 2006; 47(8): 1255 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. van Westreenen, M. Westerterp, P. L. Jager, H. M. van Dullemen, G. W. Sloof, E. F.I. Comans, J. J. B. van Lanschot, T. Wiggers, and J. Th.M. Plukker Synchronous Primary Neoplasms Detected on 18F-FDG PET in Staging of Patients with Esophageal Cancer J. Nucl. Med., August 1, 2005; 46(8): 1321 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. van Westreenen, D. C.P. Cobben, P. L. Jager, H. M. van Dullemen, J. Wesseling, P. H. Elsinga, and J. Th. Plukker Comparison of 18F-FLT PET and 18F-FDG PET in Esophageal Cancer J. Nucl. Med., March 1, 2005; 46(3): 400 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.L. van Westreenen, M. Westerterp, P.M.M. Bossuyt, J. Pruim, G.W. Sloof, J.J.B. van Lanschot, H. Groen, and J.Th.M. Plukker Systematic Review of the Staging Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer J. Clin. Oncol., September 15, 2004; 22(18): 3805 - 3812. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
